The ability of [18F]- SiF Alin - TATE to image neuroendocrine tumors using a PET-Scan compared with [18F] - FDOPA imaging

Diagnostic ability comparison between [18F]- SiF Alin - TATE and [18F] - FDOPA for Neuro-Endocrine Tumor (NET) patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2021-002161-17-CY

Enrollment

Registered

2021-08-10

Start date

2021-07-02

Completion date

Unknown

Last updated

2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Imaging capabilities of the drug on patients with neuro endocrine tumors for better investigations

Interventions

Product Name: SiF - Alin - TATE Pharmaceutical Form: Solution for injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients ith NET Older than 18 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 5

Exclusion criteria

Exclusion criteria: Pregnant Not consented Simultaneously other tumor

Design outcomes

Primary

Measure	Time frame
Main Objective: Diagnostic capability of the new radiopharmaceutical SiF - Alin -TATE campared to FDOPA to patients suffering from NET;Secondary Objective: Quantitative absorption of the tumor to the two different radiopharmaceuticals;Primary end point(s): Whether the radiopharmaceutical under investigation can be of a better use than the already existing one;Timepoint(s) of evaluation of this end point: once 20 patients have gone through the examination	—

Measure

Time frame

Main Objective: Diagnostic capability of the new radiopharmaceutical SiF - Alin -TATE campared to FDOPA to patients suffering from NET;Secondary Objective: Quantitative absorption of the tumor to the two different radiopharmaceuticals;Primary end point(s): Whether the radiopharmaceutical under investigation can be of a better use than the already existing one;Timepoint(s) of evaluation of this end point: once 20 patients have gone through the examination

—

Secondary

Measure	Time frame
Secondary end point(s): N/A;Timepoint(s) of evaluation of this end point: N/A	—

Countries

Cyprus

Contacts

Public ContactKRISTIS VEVIS

GERMAN ONCOLOGY CENTER

kristis.vevis@goc.com.cy0035725208159

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026